bacara special 340 sc suspensionskoncentrat
bayer a/s - flufenacet, diflufenican, flurtamon - suspensionskoncentrat - 80 g/l flufenacet; 200 g/l diflufenican; 60 g/l flurtamon
bcp 203 h flydende middel
fmc europe nv, agrochemical products group - linuron, clomazon - flydende middel - 250 g/l linuron; 45 g/l clomazon
maister od od-formulering
bayer a/s - foramsulfuron, iodosulfuron-methyl-na, iodosulfuron, isoxadifen-ethyl, isoxadifen - od-formulering - 30 g/l foramsulfuron; 1 g/l iodosulfuron-methyl-na; (~ 0,932 g/l iodosulfuron; 30 g/l isoxadifen-ethyl; (~ 27,2 g/l isoxadifen
tricera emulsionskoncentrat
adama northern europe b.v. - clopyralid, fluroxypyr, 2,4-d - emulsionskoncentrat - 30 g/l clopyralid; 75 g/l fluroxypyr; 375 g/l 2,4-d
vydate 10l flydende middel
du pont danmark aps - oxamyl - flydende middel - 100 g/l oxamyl
vegas olie i vand emulsion
certis europe bv - cyflufenamid - olie i vand emulsion - 51,3 g/l cyflufenamid
grounded flydende middel
helena chemical company - uspecificeret - flydende middel - 0 g/l uspecificeret
xerton suspensionskoncentrat
upl europe ltd. (tidligere: united phosphorus ltd.) - ethofumesat - suspensionskoncentrat - 417 g/l ethofumesat
busilvex
pierre fabre medicament - busulfan - hematopoietisk stamcelletransplantation - antineoplastiske midler - busilvex efterfulgt af cyclophosphamid (bucy2) er indiceret som konditionerende behandling før konventionelle hæmatopoietiske stamceller celle transplantation (hpct) hos voksne patienter, når kombinationen er betragtes som den bedste tilgængelige mulighed. busilvex følgende fludarabine (fb) er angivet som condition behandling forud for hæmatopoietisk stamcelletransplantation (hpct) hos voksne patienter, der er kandidater til en reduceret intensitet conditioning (ric) opskrift. busilvex efterfulgt af cyclophosphamid (bucy4) eller melphalan (bumel) er angivet som condition behandling forud for konventionelle hæmatopoietisk stamcelletransplantation i pædiatriske patienter.
trecondi
medac gesellschaft für klinische spezialpräparate mbh - treosulfan - hematopoietisk stamcelletransplantation - antineoplastiske midler - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.